MORE►
BrightEdge
Signify Bio co-founders, from left: CEO R.A. Session II and Chief Scientific Officer Daniel Siegwart, Ph.D., of UT Southwestern. {Photos: Taysha Gene Therapies/UTSW]
Dallas’ Signify Bio Launches With Oversubscribed $15M Financing, Partnership With UT Southwestern
by Lance Murray | Jun 5, 2025
Co-founded by Chief Scientific Advisor Daniel J. Siegwart of UT Southwestern and CEO RA Session II, Signify Bio said it harnesses the human body for the production of in situ protein therapeutics. The round was led by Actium Group with participation from the Gates Foundation Strategic Investment Fund, Danaher Ventures LLC, Eli Lilly and Company, and BrightEdge, the American Cancer Society's VC arm.
by Lance Murray |
Mar 24, 2025
Jibe Therapeutics is developing a next-generation cancer treatment that helps the immune system better recognize and attack tumors. As a result of its "Golden Ticket" pitch competition win, Jibe is relocating its research operations to Dallas' Pegasus Park.
MORE►
by Lance Murray |
Nov 6, 2023
The gift, the largest to date for BrightEdge, will fund a "first-of-its-kind program" called the ACS BrightEdge Texas Accelerator. The two-year pilot innovation program will invest in cutting-edge companies making headway in the fight to eliminate cancer.
MORE►
by Quincy Preston |
Oct 16, 2023
The NFL and NBA icons—Clark Hunt and Dirk Nowitzki—will kick off and wrap up discussions on innovation and investment. They add to an "impressive speaker lineup" including Nextdoor Co-Founder Nirav Tolia and other trailblazing speakers. Here's the full roster.
MORE►
